Acute monocytic leukemia

This study tests whether giving a chemotherapy drug (decitabine) plus a targeted therapy (ruxolitinib, fedratinib, or pacritinib) before a stem cell transplant helps people with advanced myeloproliferative neoplasms (MPN) get to transplant and have better outcomes. About 25 adult…

This study tests a new mix of drugs for people newly diagnosed with a specific type of acute myeloid leukemia (AML). The treatment combines a targeted drug (venetoclax) with two chemotherapy drugs, then switches to another chemo drug plus venetoclax. The goal is to see if this ap…

This study tests whether a targeted drug called gemtuzumab ozogamicin can clear tiny amounts of leukemia that remain after initial treatment in adults with acute myeloid leukemia (AML). The drug works like a smart bomb, attaching to a protein on cancer cells and delivering a chem…

This study tests a radioactive antibody (211At-BC8-B10) that seeks out and attacks cancer cells, followed by a donor stem cell transplant for people with high-risk leukemia or myelodysplastic syndrome (MDS) that has returned or not responded to treatment. The goal is to find the …

This study compares two treatments for acute monocytic leukemia, a blood cancer. About 204 people aged 14 to 60 will get either a new drug combo (venetoclax plus CACAG) or standard chemotherapy (3+7). The goal is to see which approach leads to more complete remissions after one c…

This phase II trial is testing two different methods to reduce graft-versus-host disease (GVHD) in patients with acute leukemia or myelodysplastic syndrome (MDS) who are receiving a donor stem cell transplant. One method removes certain immune cells from the donor cells before tr…

This study tests a new drug called STX-0712 in people with advanced types of blood cancer (CMML or AML) who have run out of standard treatments. The main goal is to find a safe dose and see how the body handles the drug. About 105 participants will take part in this early-phase t…

This early-stage study tests whether adding mitoxantrone to the usual venetoclax+azacitidine regimen can help adults with acute myeloid leukemia (AML) whose cancer did not respond or came back after initial treatment. About 30 participants will receive different doses to find the…

This study tests a combination of three drugs (venetoclax, azacytidine, and chidamide) in people newly diagnosed with a specific type of leukemia (acute monocytic leukemia) who are not healthy enough for intensive chemotherapy. The goal is to see if this drug mix can put the canc…

This study looks at whether a tailored exercise program can help older blood cancer survivors slow down the aging process. Researchers will enroll 180 people aged 50 and older who have had blood cancer. The goal is to see if participants can stick with the exercise plan and if it…